ABSTRACT
A total of 91 beedi workers were analyzed for the pattern of cutaneous lesions. Period of rolling beedi ranged from 2 months to 40 years. Dermatological findings included; callosities seen in 51 (56.04%) of workers on fingers and feet, nail changes in 22 (24.18%) like pigmentation, paronychia, dystrophy which were more prominent on the right index finger, fungal infections in 15 and eczemas in 29. Callosities and localised nail changes can be considered to be occupational marks in beedi rollers correlated to use of scissors for cutting leaves and use of gum and artificial metallic nails for rolling beedis.
ABSTRACT
BACKGROUND: The NASA/American Cancer Society (ACS) flow cytometer can simultaneously measure electronic nuclear volume (ENV) and DNA content of nuclei. The preceding articles in this volume ("NASA/American Cancer Society High-Resolution Flow Cytometer Project-I") described the schematics, performance, and procedures used for the preparation of nuclei for analysis on this unit. In the present article, we describe the analysis of selected human tumors using the ratio of ENV/DNA content (nuclear packing efficiency [NPE]). METHODS: Tumor specimens (frozen) were minced with scalpels and stained with 1-10 microg/ml of 4',6-diamidino-2-phenylindole (DAPI) dihydrochloride at pH 6.0-7.2. Trout erythrocytes were used as internal standards. Data on ENV and DNA content were collected in list mode files. Propidium iodide-stained nuclei, analyzed on a Coulter XL cytometer, were used for comparison. RESULTS: Simultaneous measurement of ENV and DNA makes it possible to discriminate between hypodiploid or hyperdiploid tumor cells, as well as to differentiate between near-diploid aneuploid and diploid cells on the basis of their increased ENV. The NPE ratio is a valuable parameter for the detection of small quantities of tumor cells, separating overlapping diploid and aneuploid populations for cell cycle analysis and characterizing the level of differentiation in some tumors. CONCLUSION: NPE analysis provides unique measuring capabilities for the study of human solid tumors by flow cytometry.
Subject(s)
American Cancer Society , Cell Nucleus/pathology , DNA/analysis , Flow Cytometry/methods , Neoplasms/pathology , United States National Aeronautics and Space Administration , Aneuploidy , Female , Humans , Indoles , Male , Neoplasms/diagnosis , Neoplasms/genetics , Ploidies , United StatesABSTRACT
Incubation of drug-resistant human tumor cells with a combination of prochlorperazine and dipyridamole has additive/synergistic effect on the cellular retention and cytotoxicity of doxorubicin. In patients administered a fixed dose of doxorubicin and prochlorperazine with escalating doses of dipyridamole, mean plasma levels of dipyridamole and prochlorperazine achieved were as high as 3.01 +/- 0.41 microm and 0.94 +/- 0.09 microm, respectively. Plasma samples from patients were analyzed in an in vitro assay to monitor the effect on the cellular retention of tritium-labeled daunorubicin in MDR1-transfected P388 cells. In 22 of 49 of the plasma samples analyzed, the daunorubicin in efflux blocking activity was one-half or greater than that of cells incubated with 12.5 microM verapamil, a well-known efflux blocker. These observations suggest that a combination of prochlorperazine and dipyridamole may enhance cellular doxorubicin retention by blocking efflux while reducing normal tissue toxicity and unwanted side effects in vivo.
Subject(s)
Antineoplastic Agents/pharmacokinetics , Dipyridamole/pharmacology , Doxorubicin/pharmacokinetics , Prochlorperazine/pharmacology , Animals , Antineoplastic Agents/metabolism , Area Under Curve , Cell Survival/drug effects , Colonic Neoplasms/drug therapy , Colonic Neoplasms/pathology , Culture Media/chemistry , Culture Media/pharmacology , Daunorubicin/metabolism , Daunorubicin/pharmacokinetics , Dipyridamole/pharmacokinetics , Dose-Response Relationship, Drug , Doxorubicin/blood , Doxorubicin/metabolism , Drug Resistance, Neoplasm , Drug Synergism , Humans , Infusions, Intravenous , Metabolic Clearance Rate , Neoplasms/drug therapy , Neoplasms/metabolism , Neoplasms/pathology , Plasma/chemistry , Prochlorperazine/pharmacokinetics , Tumor Cells, CulturedABSTRACT
A survey was conducted to find out the pattern of skin diseases among patients who attended the fortnightly medical camp held in Bantwal Taluq, a rural area. Infective disorders were found in 42.68% and non infective in 41.58%. Among the infective disorders fungal infections were most common (24.08%). Among the non infective dermatoses eczemas were most common (33.93%). On comparing the proportional infectivity rate of infectious diseases among males and females it was found that in scabies males were more affected than females.
ABSTRACT
To develop an objective, fast, and simply performed screening protocol for cis -platinum (CP) ototoxicity, we compared the efficacy of screening with distortion-product otoacoustic emissions (DPOAEs) with the outcome of both conventional and ultra-high-frequency (UHF) audiometry. Baseline audiometric and DPOAE testing was performed in 66 patients, 33 of whom met criteria for inclusion in the final database. Comparisons were made between baseline measurements and those recorded before subsequent CP infusions. Outcomes were analyzed clinically and with paired repeated-measures analysis of variance. Results indicated that DPOAEs and UHF were better measures than conventional audiometry. Further, DPOAEs may be better suited for screening older patients receiving CP chemotherapy because DPOAEs are as sensitive as UHF and are present in a greater number of these patients. Screening with DPOAEs may be enhanced by testing only in the 3- to 5.2-kHz range, thus decreasing testing time. Higher time averages to increase the signal-to-noise ratio and use of this narrower bandwidth might also allow for accurate bedside testing.
Subject(s)
Antineoplastic Agents/pharmacology , Audiometry , Cisplatin/pharmacology , Otoacoustic Emissions, Spontaneous/drug effects , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Prospective StudiesABSTRACT
Somatostatin receptor expression, which was not a previously described marker for Hürthle cell cancer of the thyroid, was demonstrated by in vivo imaging with (111)In-pentetreotide in three patients. This phenomenon not only adds another imaging technique to the nuclear medicine armamentarium for detecting recurrent and metastatic cancer in patients with Hürthle cell cancer but also opens up an alternative therapeutic avenue with somatostatin analogs or their radiolabeled compounds.
Subject(s)
Adenoma, Oxyphilic/metabolism , Receptors, Somatostatin/analysis , Thyroid Neoplasms/metabolism , Adenoma, Oxyphilic/diagnostic imaging , Aged , Humans , Indium Radioisotopes , Male , Middle Aged , Octreotide/analogs & derivatives , Pentetic Acid/analogs & derivatives , Radionuclide Imaging , Radiopharmaceuticals , Thyroid Neoplasms/diagnostic imagingABSTRACT
A case of dermatomyositis in a young girl of 18 years is reported. Though it is generally held that it is a very recalcitrant condition, we found that the patient improved by all parameters to treatment with methotrexate and steroids in three weeks.
ABSTRACT
OBJECTIVES: To determine the relative frequency of clubbing in small cell lung carcinoma (SCLC) versus non-small cell lung carcinoma (NSCLC). DESIGN: Examine patients with lung cancer for digital clubbing and relate the findings to the histopathologic subtype of lung cancer. SETTING: Cancer center at a tertiary teaching hospital. PATIENTS OR PARTICIPANTS: One hundred and eleven consecutive patients with a pathological diagnosis of lung cancer examined by one physician (KSS). INTERVENTIONS: None. MEASUREMENTS AND RESULTS: Clubbing was present in 32 (29%) of the 111 patients with lung cancer. Clubbing was more common in women (40%) than in men (19%; chi2 test p = 0.011), and was more common in patients with NSCLC (35%) than those with SCLC (4%; chi2 test p = 0.0036). CONCLUSION: In a prospective study, digital clubbing was less frequently observed in men than women and in patients with SCLC than NSCLC. These clinical observations may assist in the initial evaluation of patients for planning workup and therapy.
Subject(s)
Carcinoma, Non-Small-Cell Lung/complications , Carcinoma, Small Cell/complications , Lung Neoplasms/complications , Osteoarthropathy, Secondary Hypertrophic/etiology , Female , Humans , Male , Prospective StudiesABSTRACT
BACKGROUND: The authors had previously reported preliminary results of a treatment regimen of concurrent hyperfractionated radiation therapy and chemotherapy in patients with locally advanced head and neck carcinoma that demonstrated both feasibility and high local control. In an attempt to reduce acute mucosal and hematologic toxicity, granulocyte-colony stimulating factor (G-CSF) was added during the second phase of this study. METHODS: Seventy patients (53 with Stage IV and 17 with Stage III disease) were entered between May 1988 and June 1995 into a Phase I/II trial of concurrent radiation therapy (74.4 gray (Gy) total dose; 1.20 Gy twice daily), 5-fluorouracil (1000 mg/m2/24 hours for 72 hours), and cisplatin (50 mg/m2) for 3 cycles with the addition of mitomycin C (8 mg/m2) in Cycle 2. G-CSF was added after the initial entry of 34 patients. RESULTS: At a median follow-up of 41 months (range, 12-80 months), 44 patients were alive with a projected median overall survival of 54 months. Grade 3/4 mucositis, observed in 65% of patients, was equally prevalent and prolonged in both G-CSF-treated (+) and G-CSF-naive (-) patients. Grade 3/4 leukopenia was present in 45% and 36% of G-CSF- and G-CSF+ patients, respectively. The 3-year locoregional control and cause specific survival rates were 68% and 75%, respectively. CONCLUSIONS: This regimen was feasible and effective but caused severe mucositis. No benefit was derived from the addition of G-CSF. This regimen deserves further modification to reduce acute mucositis toxicity yet maintain the high locoregional control rate.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cisplatin/administration & dosage , Combined Modality Therapy , Feasibility Studies , Female , Fluorouracil/administration & dosage , Granulocyte Colony-Stimulating Factor/therapeutic use , Humans , Male , Middle Aged , Mitomycin/administration & dosage , Multivariate Analysis , Proportional Hazards Models , Radiotherapy, High-Energy/adverse effects , Statistics, Nonparametric , Survival AnalysisABSTRACT
This Kap (Knowledge, Attitude, Practical) study was to assess the current level of knowledge among first year M.B.B.S. students about AIDS at the point of entry to medical course. One hundred and seventy-one students were given a pre-tested close ended questionnaire. Overall level of knowledge about AIDS was found to be 64.91%. Male students were found to have better knowledge regarding transmission and prevention of AIDS than female students. Misconceptions were found to exist regarding mode of transmission, prognosis and prevention. Awareness programmes should be initiated among M.B.B.S. students in the first year itself, so that, lacunae can be rectified.
ABSTRACT
A high-performance liquid chromatographic method has been developed and tested for simultaneous extraction, elution and determination of doxorubicin and prochlorperazine content in human plasma samples. The procedure consists of extraction through a conditioned C18 solid-phase extraction cartridge, elution from a Spherisorb C8 reversed-phase column by an isocratic mobile phase (60% acetonitrile, 15% methanol and 25% buffer) followed by detection with electrochemical and fluorescence detectors. Recovery of doxorubicin and prochlorperazine from pooled human plasma samples (n=3) containing 100 ng/ml of the two drugs was 77.8+/-3.5% and 89.1+/-6.0%, respectively. The lower limits of quantitation for doxorubicin and prochlorperazine in plasma samples were 6.25 ng/ml and 10 ng/ml, respectively. A linear calibration curve was obtained for up to 2 microg/ml of doxorubicin and prochlorperazine. This combination method may be of particular value in clinical studies where phenothiazines such as prochlorperazine are used to enhance retention of doxorubicin in drug resistant tumor cells.
Subject(s)
Antibiotics, Antineoplastic/blood , Chromatography, High Pressure Liquid/methods , Doxorubicin/blood , Prochlorperazine/blood , Antibiotics, Antineoplastic/administration & dosage , Antibiotics, Antineoplastic/pharmacokinetics , Chlorpromazine/blood , Circadian Rhythm , Daunorubicin/blood , Doxorubicin/administration & dosage , Doxorubicin/pharmacokinetics , Humans , Infusions, Intravenous , Linear Models , Predictive Value of Tests , Prochlorperazine/administration & dosage , Prochlorperazine/pharmacokinetics , Reproducibility of Results , Sensitivity and Specificity , Spectrometry, Fluorescence , Time FactorsABSTRACT
The objective of this review is to make physicians aware of new radionuclide methods to detect cardiac effects of chemotherapeutic drugs. This knowledge is important because of the limitations of the physical examination and the electrocardiogram for detecting early reversible cardiac damage. Presently left ventricular ejection fraction (LVEF) is routinely used to screen for cardiotoxicity. Since LVEF obtained by radionuclide angiocardiography is more accurate than the LVEF estimated by echocardiography, serial radionuclide LVEF monitoring is most commonly used to monitor cardiotoxicity. Diastolic measurements of left ventricular function (such as peak filling rate) are now being added to routine LVEF measurements to enhance standard radionuclide evaluation. This screening test should be done prior to beginning therapy and at appropriate points based on the baseline study, therapy scheme and the patient's clinical status. At some centers, exercise LVEF methods are being used to determine if cardiac reserve is adequate for the patient to tolerate additional chemotherapy when cardiac injury may be present. Previously, endomyocardial biopsy was needed to detect and confirm early anthracycline cardiotoxicity. This invasive test may be replaced by a new noninvasive in vivo method using radioactive monoclonal antibodies against cardiac muscle (indium-111-antimyosin). Because cardiac failure has been associated with adrenergic neuron injury, it has been proposed that radioactive methyliodobenzylguanine may detect the adrenergic abnormality which may predict future development of congestive heart failure or sudden death months after therapy is discontinued. Advantages and disadvantages of these methods in evaluating cardiotoxicity, and an algorithm to optimally monitor antitumor therapy-induced cardiomyopathy are discussed.
Subject(s)
Antibiotics, Antineoplastic/adverse effects , Cardiomyopathies/chemically induced , Doxorubicin/adverse effects , Drug Monitoring/methods , Heart/diagnostic imaging , Ventricular Function, Left/physiology , Cardiomyopathies/diagnosis , Humans , Radionuclide Imaging , Stroke VolumeABSTRACT
Induction chemotherapy followed by radiation has been extensively studied in an effort to improve local control and possibly overall survival of patients with locally advanced head and neck cancer. From June 1989 until May 1991, 39 patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) were treated with 3 cycles of induction chemotherapy, consisting of cisplatin (100 mg/m2 d 1) and fluorouracil (1000 mg/m2 d 2-6) followed by radiation potentiated by weekly administration of carboplatin (60 mg/m2). Surgery was performed in selected patients with residual disease after the combined modality approach. Four cycles of adjuvant chemotherapy with carboplatin (325 mg/m2) and bleomycin (15 u) were administered in those patients who demonstrated a partial response after locoregional treatment. There were 36 men and 3 women with a median age of 56 (range 39-74) years and Karnofsky performance status of 70 (range 60-100). The primary site of the tumor was nasopharynx (8), oropharynx (8), hypopharynx (3), oral cavity (4), larynx (13), paranasal sinus (2), and salivary glands (1). Thirty-two (82%) patients presented with stage IV disease. After the completion of induction chemotherapy, 14 (36%, 95% CI 21-53%) patients achieved a complete response (CR). This CR rate was increased to 56% (95% CI, 42-74%) after locoregional treatment. Main toxicities included nausea/vomiting (56%), leukopenia (40%), anemia (30%), thrombocytopenia (10%), stomatitis (28%), diarrhea (17%), and alopecia (12%). Median relapse-free survival was 18 (1-50) months, median time to progression was 13 (0.3-58.5) months, and median survival 19 (0.3-59) months. Induction chemotherapy with cisplatin and fluorouracil followed by radiation potentiated with carboplatin is feasible. However, this combined modality approach, as applied in the present study, does not appear to yield superior results than those reported with chemotherapy followed by radiation alone.
Subject(s)
Antineoplastic Agents/administration & dosage , Carboplatin/administration & dosage , Carcinoma, Squamous Cell/drug therapy , Cisplatin/administration & dosage , Fluorouracil/administration & dosage , Head and Neck Neoplasms/therapy , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Squamous Cell/radiotherapy , Chemotherapy, Adjuvant , Combined Modality Therapy , Female , Head and Neck Neoplasms/drug therapy , Head and Neck Neoplasms/radiotherapy , Humans , Male , Middle Aged , Patient Compliance , Survival AnalysisABSTRACT
This retrospective study determined the clinical course of lung cancer in patients with human immunodeficiency virus (HIV) infection. A total of 23 patients with HIV infection archived as lung cancer were studied: 16 were identified from about 1,000 lung cancer patients entered in the tumor registry and medical records of Jackson Memorial Hospital, 7 were identified from about 1,000 HIV-positive patients entered in the Special Immunology registry of Veterans Administration Medical Center, 4 patients did not have pathologic confirmation of lung cancer, and 19 patients, all men, met the criteria for analysis (histopathologic diagnosis of lung cancer and HIV+ by serology). The median age was 47 (range: 36-66). Risk factors for HIV were homosexuality (6 patients), blood transfusion (3), promiscuity (5), intravenous drug abuse (4), and none (3). Six patients had a history of coexistent pulmonary tuberculosis and 5 had Pneumocystis carinii pneumonia. Median survival from diagnosis of lung cancer was 3 months. Advanced stages of both HIV infection and lung cancer may account for the poor survival. All patients were men and noted to be younger than other patients with lung cancer.
Subject(s)
HIV Infections/complications , Lung Neoplasms/epidemiology , Lung Neoplasms/etiology , Adult , Aged , Florida/epidemiology , HIV Infections/epidemiology , Humans , Lung Neoplasms/virology , Male , Middle Aged , Population Surveillance , Prognosis , Registries , Retrospective Studies , Risk Factors , Survival RateABSTRACT
DNA ploidy of pepsin digested preparations of 48 paraffin-embedded specimens from 19 patients with histologically confirmed malignant mesothelioma was determined by laser flow cytometry. Eight of the 19 tumors (42%) were diploid and 11 (58%) were aneuploid. Of the aneuploid tumors, only one showed multiploidy. The median survival time of the patients with diploid tumors was 19, 16, and 14 months from the onset of symptoms, diagnosis, and treatment, respectively. The median survival in patients with aneuploid tumors was 8, 7, and 7 months from the onset of first symptoms, diagnosis, and treatment. Thus, patients with diploid tumors lived longer than patients with aneuploid tumors. These results suggest that DNA ploidy analysis may be of prognostic value in malignant mesothelioma.
Subject(s)
Aneuploidy , DNA, Neoplasm/analysis , Mesothelioma/pathology , Pleural Neoplasms/pathology , Adult , Aged , Cell Cycle , Female , Flow Cytometry , Humans , Male , Mesothelioma/genetics , Middle Aged , Paraffin Embedding , Pleural Neoplasms/genetics , PrognosisABSTRACT
The power-line frequency interference in electrocardiographic signals is eliminated to enhance the signal characteristics for diagnosis. The power-line frequency normally varies +/- 1.5 Hz from its standard value of 50 Hz. In the present work, the performances of the linear FIR filter, Wave digital filter (WDF) and adaptive filter for the power-line frequency variations from 48.5 to 51.5 Hz in steps of 0.5 Hz are studied. The advantage of the LMS adaptive filter in the removal of power-line frequency interference even if the frequency of interference varies by +/- 1.5 Hz from its normal value of 50 Hz over other fixed frequency filters is very well justified. A novel method of integrating rule-based system approach with linear FIR filter and also with Wave digital filter are proposed. The performances of Rule-based FIR filter and Rule-based Wave digital filter are compared with the LMS adaptive filter.
Subject(s)
Electrocardiography/methods , Algorithms , Electrocardiography/statistics & numerical data , Evaluation Studies as Topic , Humans , Signal Processing, Computer-Assisted/instrumentationABSTRACT
OBJECTIVE: The radiographic manifestations of bronchogenic carcinoma in HIV-positive individuals may resemble or accompany changes of inflammatory disease. To provide information that is useful in the differential diagnosis, we studied the findings on plain radiographs and chest CT scans in 30 HIV-positive patients with proven bronchogenic carcinoma and correlated the radiographic features with the presence or absence of thoracic opportunistic infection. SUBJECTS AND METHODS: Thirty HIV-positive individuals had bronchogenic carcinoma diagnosed at our institution between 1986 and 1993. Fourteen (47%) of the 30 had AIDS at the time of cancer diagnosis. All but one of the patients were men, and the median age at diagnosis was 48 years (range, 32-66 years). Most (90%) had a history of smoking. Eighteen (60%) of the 30 had a history of pulmonary tuberculosis, Pneumocystis carinii pneumonia, or both. We retrospectively reviewed all available chest radiographs (n = 27) and chest CT scans (n = 25) for tumor size and location, adenopathy, pleural disease, and pulmonary infiltrates. RESULTS: Eighteen tumors (60%) were peripheral, 11 (37%) were central (hilar or mediastinal), and one manifested as a metastatic pleural mass. Of the peripheral tumors, 17 (94%) were in the upper lobes. All the central tumors showed obstructive consolidation of lung in the distribution of the affected airway. Adenopathy was present in 63% of the patients, and pleural effusions or masses were seen in 33%. A history of tuberculosis or Pneumocystis carinii pneumonia was present in 83% of the patients with peripheral tumors but only 27% of the patients with central lesions (p = .005). Superimposed infiltrates were present in six patients (20%). Three (17%) of 18 peripheral tumors were obscured by or mistaken for inflammatory disease, delaying the diagnosis of cancer. CONCLUSION: Bronchogenic carcinoma usually manifests as a peripheral upper lobe mass in HIV-positive patients with a history of tuberculosis or Pneumocystis carinii pneumonia, whereas central masses are more common in patients without a history of thoracic opportunistic infection. Carcinoma should be suspected in patients with peripheral lesions that persist despite appropriate antibiotic therapy.
Subject(s)
Carcinoma, Bronchogenic/diagnostic imaging , HIV Seropositivity/complications , Lung Neoplasms/diagnostic imaging , AIDS-Related Opportunistic Infections/complications , AIDS-Related Opportunistic Infections/diagnostic imaging , Adult , Aged , Carcinoma, Bronchogenic/complications , Female , HIV Infections/complications , Humans , Lung/diagnostic imaging , Lung Neoplasms/complications , Male , Middle Aged , Pneumonia, Pneumocystis/complications , Pneumonia, Pneumocystis/diagnostic imaging , Radiography, Thoracic , Retrospective Studies , Tomography, X-Ray Computed , Tuberculosis, Pulmonary/complications , Tuberculosis, Pulmonary/diagnostic imagingABSTRACT
Initially, 109 evaluable patients with locally advanced or metastatic small cell lung cancer (SCLC) were treated with vincristine, Adriamycin, procarbazine, and etoposide (VAPE). Partial (PR) or nonresponders (NR) were crossed to CCM (cyclophosphamide, CCNU, and methotrexate) and then to HMiVe (hexamethylmelamine, mitomycin C, vinblastine) sequentially at maximum response. Complete responders (CR) were intensified by 50% with VAPE primarily and randomized to VAPE, alternating with CCM or CCM alone during maintenance. CR patients with limited disease received local thoracic irradiation and prophylactic cranial irradiation (PCI), whereas those with extensive disease received PCI alone. There were 45 patients (41%) who achieved a CR to chemotherapy, and 27 patients were eligible for randomization. Of 12 CR patients randomized to alternating therapy (VAPE/CCM), the median survival was 25.9 months compared to 12.9 months for 15 CR patients randomized to continuous CCM (P = .049). In addition, 35 patients achieved a PR (32%) and 29 were NR (27%). Overall median survivals were significantly different for the CR patients (13.0 months) as compared to PR (7.6 months) and NR patients (6.4 months). Late intensification did not appear to add substantially to survival while contributing to toxicity. In summary, VAPE is a new outpatient regimen for SCLC, which is highly effective as an induction regimen with moderate hematologic toxicity and predominantly gastrointestinal nonhematologic toxicity.